
This segment of Marghoob’s interview featured a discussion of pigmented lesion identification and use of technology such as AI.

This segment of Marghoob’s interview featured a discussion of pigmented lesion identification and use of technology such as AI.

Only 6.7% of patients with an abnormal protein dipstick test result had guideline-recommended follow-up albuminuria testing.

These new data demonstrate that bimekizumab was both effective and well-tolerated over the course of 2 years for patients with hidradenitis suppurativa.

The AI model, SLIViT, improves accuracy and efficiency in interpreting 3D medical scans, outperforming traditional methods and reducing specialists' workload.

This month in review spotlights HCPLive’s coverage of the top hepatic pipeline news and research from September, covering hepatitis, PBC, MASH/MASLD, and more.

Ruxolitinib cream offers an effective nonsteroidal treatment for mild to moderate atopic dermatitis, with proven efficacy and safety for sensitive skin areas.

Steve Nissen, MD, discusses how the cardiology community needs to learn from previous mistakes in uptake of LDL-C lowering therapies as it approaches an age of Lp(a)-lowering agents.

Elucid has received 510(k) clearance for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease.

A study links conversion therapy with worse mental health, such as PTSD and depression, showing a need for legislative action and support for LGBTQ+ individuals.

Pfizer has announced the voluntary withdrawal of voxelotor in all markets after a report found the benefits do not outweigh the risks for sickle cell disease.

The approval marks the fourth biosimilar approved for ustekinumab, for all approved indications.

Subclinical atherosclerosis burden and its progression are independently linked to the risk of death from any cause in asymptomatic individuals.

The designation was based on positive data from the phase 2b FASCINATE trial of denifanstat in noncirrhotic MASH with moderate to advanced fibrosis.

In this interview, Marghoob highlights some of the biggest diagnostic challenges faced by dermatologists and other providers when it comes to pigmented lesions.

This Month in Review features the approval of trospium chloride capsules (Cobenfy) as well as other clinical trials in the psychiatry field.

New data presented by Sun Pharma at EADV 2024 highlight the impact of deuruxolitinib 8 mg treatment of adults with severe alopecia areata.

Family Heart Foundation announces the launch of Cholesterol Connect, a program that provides free at-home lipid screening and personalized support.

Bau explains the challenges of using MELD to determine liver transplant referrals and other complexities of the evaluation process.

Ascendis Pharma has submitted a sBLA to the FDA for TransCon hGH for the treatment of adults with growth hormone deficiency.

Positive 120-day data from the phase 2a study of CNP-104 in PBC highlight its efficacy across multiple immunological and clinical measurements

Phentolamine ophthalmic solution 0.75% effectively reversed pharmacologically-induced pupil dilation in the MIRA-2 and MIRA-3 clinical trials.

In this episode, Tina Bhutani, MD, MAS, joins The Medical Sisterhood for a discussion about confronting imposter syndrome as a woman in medicine.

A study found pregnant patients with IgA nephropathy and adverse pregnancy outcomes were less likely to achieve proteinuria remission, though renal function remained unaffected.

Compared to those without SLD, patients with MASLD, MetALD, and other combination etiology had a greater risk of developing liver and gastrointestinal cancers.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

Individuals diagnosed with retinitis pigmentosa experienced an elevated risk of depressive disorder, compared with the general Korean population.

In this interview at EADV, Thaçi was asked to highlight his team’s recent data from the ARCADIA trial program on nemolizumab for patients with eczema.

HCPLive spoke to Rodriguez, MD, MPH, about implementing AI in cardiology care.

Alcohol intake frequency was linked to a greater risk of IgAN, while dietary exposures like cheese, cereal, and sushi were associated with a reduced risk.

To date, biosimilars have supported 495 million incremental days of therapy that patients would otherwise not have received.